126 related articles for article (PubMed ID: 34440070)
1. Synergistic AHR Binding Pathway with EMT Effects on Serous Ovarian Tumors Recognized by Multidisciplinary Integrated Analysis.
Su KM; Gao HW; Chang CM; Lu KH; Yu MH; Lin YH; Liu LC; Chang CC; Li YF; Chang CC
Biomedicines; 2021 Jul; 9(8):. PubMed ID: 34440070
[TBL] [Abstract][Full Text] [Related]
2. Expression of selected epithelial-mesenchymal transition transcription factors in serous borderline ovarian tumors and type I ovarian cancers.
Sadlecki P; Jóźwicki J; Antosik P; Grabiec M
Tumour Biol; 2018 Jun; 40(6):1010428318784807. PubMed ID: 29952249
[TBL] [Abstract][Full Text] [Related]
3. Dysregulated Immunological Functionome and Dysfunctional Metabolic Pathway Recognized for the Pathogenesis of Borderline Ovarian Tumors by Integrative Polygenic Analytics.
Chang CM; Li YF; Lin HC; Lu KH; Lin TW; Liu LC; Su KM; Chang CC
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921111
[TBL] [Abstract][Full Text] [Related]
4. Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer.
Chien J; Fan JB; Bell DA; April C; Klotzle B; Ota T; Lingle WL; Gonzalez Bosquet J; Shridhar V; Hartmann LC
Gynecol Oncol; 2009 Jul; 114(1):3-11. PubMed ID: 19410283
[TBL] [Abstract][Full Text] [Related]
5. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
6. Discrepant clinicopathologic characteristics and HE4 performance in type I and type II epithelial ovarian cancer.
Jiang J; Bo D; Chang X; Cheng H; Ye X; Cui H
Int J Clin Exp Med; 2015; 8(11):21303-10. PubMed ID: 26885070
[TBL] [Abstract][Full Text] [Related]
7. Risk of specific types of ovarian cancer after borderline ovarian tumors in Denmark: A nationwide study.
Hannibal CG; Frederiksen K; Vang R; Kurman RJ; Kjaer SK
Int J Cancer; 2020 Aug; 147(4):990-995. PubMed ID: 31930502
[TBL] [Abstract][Full Text] [Related]
8. The Epithelial-Mesenchymal Transition, E-cadherin and Tumor Progression in Ovarian Serous Tumors.
Bozhkova DM; Poryazova-Markova EG
Folia Med (Plovdiv); 2019 Jun; 61(2):296-302. PubMed ID: 31301662
[TBL] [Abstract][Full Text] [Related]
9. Expression and prognostic significance of epithelial-mesenchymal transition-related markers and phenotype in serous ovarian cancer.
Song IH; Kim KR; Lim S; Kim SH; Sung CO
Pathol Res Pract; 2018 Oct; 214(10):1564-1571. PubMed ID: 30082157
[TBL] [Abstract][Full Text] [Related]
10. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
[TBL] [Abstract][Full Text] [Related]
11. Borderline ovarian tumors: Guidelines from the French national college of obstetricians and gynecologists (CNGOF).
Bourdel N; Huchon C; Abdel Wahab C; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chereau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; Mathieu D'argent E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():492-501. PubMed ID: 33262005
[TBL] [Abstract][Full Text] [Related]
12. Borderline ovarian tumors: French guidelines from the CNGOF. Part 1. Epidemiology, biopathology, imaging and biomarkers.
Huchon C; Bourdel N; Abdel Wahab C; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chereau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; Mathieu D'argent E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
J Gynecol Obstet Hum Reprod; 2021 Jan; 50(1):101965. PubMed ID: 33160106
[TBL] [Abstract][Full Text] [Related]
13. Expression of zinc finger transcription factors (ZNF143 and ZNF281) in serous borderline ovarian tumors and low-grade ovarian cancers.
Sadłecki P; Grabiec M; Grzanka D; Jóźwicki J; Antosik P; Walentowicz-Sadłecka M
J Ovarian Res; 2019 Mar; 12(1):23. PubMed ID: 30885238
[TBL] [Abstract][Full Text] [Related]
14. The stromal tumor-infiltrating lymphocytes, cancer stemness, epithelial-mesenchymal transition, and B7-H4 expression in ovarian serous carcinoma.
Hwang C; Lee HJ; Na JY; Kim KH; Song YJ; Kim JY; Kim K; Shin DH; Park JY; Kim SY; Lee JH; Choi KU
J Ovarian Res; 2023 Jan; 16(1):3. PubMed ID: 36609273
[TBL] [Abstract][Full Text] [Related]
15. Differential gene expression identifies a transcriptional regulatory network involving ER-alpha and PITX1 in invasive epithelial ovarian cancer.
Li Y; Jaiswal SK; Kaur R; Alsaadi D; Liang X; Drews F; DeLoia JA; Krivak T; Petrykowska HM; Gotea V; Welch L; Elnitski L
BMC Cancer; 2021 Jul; 21(1):768. PubMed ID: 34215221
[TBL] [Abstract][Full Text] [Related]
16. Borderline ovarian tumors: French guidelines from the CNGOF. Part 2. Surgical management, follow-up, hormone replacement therapy, fertility management and preservation.
Bourdel N; Huchon C; Abdel Wahab C; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chereau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; D'argent Mathieu E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
J Gynecol Obstet Hum Reprod; 2021 Jan; 50(1):101966. PubMed ID: 33144266
[TBL] [Abstract][Full Text] [Related]
17. An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response.
Pinciroli P; Alberti C; Sensi M; Canevari S; Tomassetti A
BMC Genomics; 2013 Jul; 14():508. PubMed ID: 23889749
[TBL] [Abstract][Full Text] [Related]
18. [Identification of key molecules in miRNA-mRNA regulatory network associated with high-grade serous ovarian cancer recurrence using bioinformatic analysis].
Zhang P; He M; Zeng Y; Cai X
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Jan; 43(1):8-16. PubMed ID: 36856205
[TBL] [Abstract][Full Text] [Related]
19. Survival of women with ovarian carcinomas and borderline tumors is not affected by estrogen and progesterone receptor status.
Sallum LF; Sarian LO; Lucci De Angelo Andrade L; Vassallo J; Soares FA; Pinto GA; Ferreira PA; Derchain S
J Gynecol Oncol; 2013 Apr; 24(2):167-76. PubMed ID: 23653835
[TBL] [Abstract][Full Text] [Related]
20. [Expression and promotor methylation of p73 gene in ovarian epithelial tumors].
Zhang YL; Guo XR; Shen DH; Cheng YX; Liang XD; Chen YX; Wang Y
Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):33-8. PubMed ID: 22455848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
